
|Videos|February 11, 2019
Emerging Themes in Targeted Therapy Research for CLL
Author(s)John F. Seymour, MBBS, PhD
John F. Seymour, MBBS, PhD, discusses some emerging themes from recent research for targeted therapies as treatment of patients with chronic lymphocytic leukemia.
Advertisement
John F. Seymour, MBBS, PhD, clinical hematologist, associate director of Clinical Research, Peter MacCallum Cancer Centre, director of the integrated Haematology Department of the Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, discusses some emerging themes in research for targeted therapies as a treatment for patients with chronic lymphocytic leukemia (CLL).
Targeted agents are here to stay, says Seymour. These agents are more effective, safer, and are less genotoxic than treatment with chemoimmunotherapy.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5








































